Should natalizumab be used despite JC virus positivity?-Commentary.
作者信息
Hedström Anna Karin
机构信息
Department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden.
出版信息
Mult Scler. 2025 Jul;31(8):920-921. doi: 10.1177/13524585251346378. Epub 2025 May 30.
Abstract
摘要
相似文献
1
Should natalizumab be used despite JC virus positivity?-Commentary.
Mult Scler. 2025 Jul;31(8):920-921. doi: 10.1177/13524585251346378. Epub 2025 May 30.
2
Should natalizumab be used despite JC virus positivity? Yes.
Mult Scler. 2025 Jul;31(8):916-918. doi: 10.1177/13524585251346374. Epub 2025 Jun 14.
3
Should natalizumab be used despite JC virus positivity? No.
Mult Scler. 2025 Jul;31(8):918-920. doi: 10.1177/13524585251346382. Epub 2025 May 30.
4
Natalizumab for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
5
Natalizumab for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
6
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267.
7
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1919-25. doi: 10.1016/j.cgh.2015.05.022. Epub 2015 May 19.
8
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.
9
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4.
10
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
本文引用的文献
1
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.
2
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.
3
Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. doi: 10.1212/NXI.0000000000000297. eCollection 2016 Dec.
4
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1.
5
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.
Zotero 插件